Quince Therapeutics, Inc. (QNCX)

NMS – Real Time Price. Currency in USD

1.26

+0.02 (1.61%)

At close: May 12, 2026, 4:00 PM EDT

1.22

-0.04 (-3.16%)

Pre-market: May 13, 2026, 5:07 AM EDT

30.03.2026

Quince Therapeutics Settles Approximately $16.4 Million of Debt

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the company's outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5 million. This marks a material milestone for Quince as the completion of the settlement resolves critical debt obligations and allows the company to advance its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder valu.

12.02.2026

Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks

Quince Therapeutics Inc (NASDAQ: QNCX) stock is trading sharply lower Thursday after the biotech company followed up Wednesday's rally with a Form 8-K that underscores how precarious its situation is. Here's what investors need to know amid this week's volatility.

10.02.2026

Quince Therapeutics Stock Explodes 300% On Strategic Review

Quince Therapeutics Inc (NASDAQ: QNCX) shares are soaring Tuesday as the company has engaged LifeSci Capital to serve as its exclusive financial advisor.

09.02.2026

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value. Strategic alternatives under consideration may include, but are not limited to, partnerships, joint ventures, mergers, acquisitions, licensing, or other strategic transactions. LifeSci Capital will also a.

29.01.2026

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced topline results from its pivotal Phase 3 NEAT clinical trial evaluating its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP), in patients with Ataxia-Telangiectasia (A-T). In the NEAT study, the company's pivotal Phase 3 in.

28.01.2026

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation of previously published safety data from the long-term treatment of children with Ataxia-Telangiectasia (A-T) at the British Paediatric Neurology Association 2026 Annual Meeting taking place in Glasgow, Scotland January 28-30, 2026. The obj.

12.01.2026

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Quince Therapeutics is rated Buy ahead of its pivotal Phase 3 NEAT trial readout in Ataxia-Telangiectasia (A-T) expected mid-Q1 2026. eDSP, QNCX's lead asset, offers chronic corticosteroid delivery with reduced toxicity, targeting a $1B+ orphan market with no approved therapies. The NEAT trial addresses prior design flaws, is 90% powered for statistical significance in 6-9 year-olds, and enjoys strong regulatory alignment.

Videos

No Data

There is no data to display

Press releases

30.03.2026

Quince Therapeutics Settles Approximately $16.4 Million of Debt

09.02.2026

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

29.01.2026

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

28.01.2026

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation of previously published safety data from the long-term treatment of children with Ataxia-Telangiectasia (A-T) at the British Paediatric Neurology Association 2026 Annual Meeting taking place in Glasgow, Scotland January 28-30, 2026. The obj.

Quince Therapeutics, Inc. (QNCX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Quince Therapeutics, Inc. (QNCX)

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks

Quince Therapeutics Stock Explodes 300% On Strategic Review

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Videos

No Data

Press releases

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks

Quince Therapeutics Stock Explodes 300% On Strategic Review

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Videos

No Data

Press releases

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Search stocks

Quince Therapeutics, Inc. (QNCX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Quince Therapeutics, Inc. (QNCX)

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks

Quince Therapeutics Stock Explodes 300% On Strategic Review

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Videos

No Data

Press releases

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks

Quince Therapeutics Stock Explodes 300% On Strategic Review

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Videos

No Data

Press releases

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting